To examine the association between mitochondrial mutagenesis and the proinfl ammatory microenvironment in patients with infl ammatory arthritis. Methods Fifty patients with infl ammatory arthritis underwent arthroscopy and synovial tissue biopsies, synovial fl uid and clinical assessment were obtained. Fifteen patients pre/post-TNFi therapy were also recruited. Normal synovial biopsies were obtained from 10 subjects undergoing interventional arthroscopy. Macroscopic synovitis/vascularity was measured by visual analogue scale. Cell-specifi c markers CD3 (T cells) and CD68 (macrophages) were quantifi ed by immunohistology. TNFα, IL-6, IFNγ and IL-1β were measured in synovial fl uids by MSD multiplex assays. Synovial tissue mitochondrial mutagenesis was quantifi ed using a mitochondrial random mutation capture assay (RMCA). The direct effect of TNFα on oxidative stress and mitochondrial function was assessed in primary cultures of rheumatoid arthritis synovial fi broblast cells (RASFCs). Mitochondrial mutagenesis, reactive oxygen species (ROS), mitochondrial membrane potential (MMP) and mitochondrial mass (MM) were quantifi ed using the RMCA and specifi c cell fl uorescent probes. Results A signifi cant increase in mtDNA mutation frequency was demonstrated in infl amed synovial tissue compared with control (p<0.05), an effect that was independent of age. mtDNA mutations positively correlated with macroscopic synovitis (r=0.52, p<0.016), vascularity (r=0.54, p<0.01) and with synovial fl uid cytokine levels of TNFα (r=0.74, p<0.024) and IFNγ (r=0.72, p<0.039). mtDNA mutation frequency post-TNFi therapy was signifi cantly lower in patients with a DAS<3.2 (p<0.05) and associated with clinical and microscopic measures of disease (p<0.05). In vitro TNFα signifi cantly induced mtDNA mutations, ROS, MM and MMP in RASFCs (all p<0.05). Conclusion High mitochondrial mutations are strongly associated with synovial infl ammation showing a direct link between mitochondrial mutations and key proinfl ammatory pathways.
INTRODUCTION
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are two of the most common forms of infl ammatory arthritis characterised by synovial infl ammation, pain and progressive damage. 1 The mechanisms involved in synovial infl ammation and invasion are not fully understood; however, an early event in infl ammation is angiogenesis, which facilitates the persistent infi ltration of immune cells into the joint resulting in destruction of adjacent articular cartilage and bone. 2 Oxidative stress arises from an imbalance between reactive oxygen species (ROS) production and the capability of opposing antioxidant forces. Mitochondria provide cellular energy through oxidative phosphorylation in the mitochondrial electron transport chain with resultant ATP production and ROS generation as a by-product. 3 Antioxidant defence systems generally mop up leaked ROS production; however, under infl ammatory and pathological conditions, ROS can exceed the capacity of antioxidant defence systems and damage occurs to lipids, proteins and DNA. DNA adducts such as 8-oxo-7,8-dihydro-2′-deoxyguanine and lipid peroxidation-inducing agents such as 4-hydroxy-2-nonenal are highly elevated in synovial fl uid and tissue of RA and PsA patients and correlate with angiogenic growth factor expression. 2 4 Oxidative damage can induce cyclooxygenase-2, angiogenesis, MMP9/13 expression, can regulate antiapoptotic pathways and can alter nuclear factor kappa B (NF-κB) signalling, key processes involved in the pathogenesis of infl ammatory arthritis. [5] [6] [7] [8] Furthermore antioxidant treatments can improve disease progression in animal models of infl ammatory arthritis. 9 10 Mitochondrial DNA (mtDNA) lacks the intrinsic repair mechanisms of nuclear DNA and is thought to be more sensitive to increased oxidative damage and thus more vulnerable to high mutation rates. 11 Mutation of the mitochondrial genome in genes encoding proteins for subunits of mitochondrial respiratory chain complexes IV, ribosomal RNA and transfer RNA have been associated with neurodegenerative diseases and cancer. [11] [12] [13] Inherited mitochondrial disease is considered a distinct entity predisposing individuals to heritable conditions such as chronic progressive external ophthalmoplegia, lebers hereditary optic neuropathy and mitochondrial myopathy, encephalopathy, lactic acidosis and stroke syndrome. 14 Furthermore, type-1 tumour necrosis factor receptor (TNFR1) mutant cells show evidence of altered mitochondrial function paralleled by increased oxidative capacity and mitochondrial ROS generation, blockade of which resulted in reduced proinfl ammatory cytokine expression. This suggests a potential role for mitochondrial ROS in the regulation of cytokine pathways in infl ammatory diseases. 15 In this study, we demonstrate a signifi cant increase in mtDNA mutation frequency in the infl amed synovium compared with normal synovium. We demonstrate for the fi rst time a signifi cant relationship between mtDNA mutation frequency with macroscopic/microscopic measures of infl ammation and with key proinfl ammatory mediators: TNFα and interferon γ (IFNγ). Finally, we demonstrate in vivo and in vitro that TNFα signifi cantly alters mtDNA mutation frequency and mitochondrial function.
MATERIALS AND METHODS

Patient selection and arthroscopy
Fifty infl ammatory arthritis patients with active disease (13 men, 37 women) were recruited prior to commencing biologic therapy (RA, n=39; PsA, n=11) fulfi lling the criteria of the American College of Rheumatology 16 and classifi cation criteria for PsA, 17 respectively, from the Rheumatology Clinic. Ten patients undergoing interventional arthroscopy for cruciate ligament tears were also recruited (eight men; two women; mean age 38 years (IQR 28-43)). All patients provided fully informed consent. The mean age of the infl ammatory arthritis cohort was 52 years (IQR 41-60) and the clinical characteristics for these patients included tender joint count 13 (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) , swollen joint count 11 (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) , erythrocyte sedimentation rate 37 mm/h (27-65), C reactive protein 29 mg/l (9-57), disease activity score (DAS) 28 5.76 (3.9-6.32) and disease duration 19 months (5-57). Sixty-fi ve per cent of patients were rheumatoid factor positive and 77% anticitrullinated protein antibody positive. A subgroup of 15 patients (RA, n=8; PsA, n=7) were assessed at baseline and 3 months post-TNF inhibitor (TNFi) therapy; their median age was 52 years (IQR 55-49), 33% were rheumatoid factor and anticyclic citrullinated protein positive. Median baseline DAS28 was 4.76 (5.2-3.4). Seven patients achieved a low disease activity state (DAS28<3.2) after 3 months of treatment according to van Gestel et al. 18 
Arthroscopy, macroscopic assessment and synovial biopsy
Under local anaesthetic, arthroscopy of the infl amed knee was performed using a Wolf 2.7 mm needle arthroscope (Richard Wolf, Vernon Hills, Illinois, USA) as previously described. 2 Macroscopic synovitis and vascularity were scored on a visual analogue scale (0-100 mm). 19 Synovial tissue biopsies were obtained by 2 mm grasping forceps, under direct visualisation, embedded in mounting media for immunohistochemical analysis or snap frozen in liquid nitrogen for mitochondrial mutagenesis analyses. Paired synovial fl uid was obtained and stored at −70°C for cytokine analysis. Control synovial biopsies were also obtained from 10 patients undergoing interventional arthroscopy for cruciate ligament tears.
Mitochondrial random mutation capture assay (RMCA)
Levels of mitochondrial point mutations in snap frozen synovial biopsies were analysed in a blinded fashion using mitochondrial RMCA as described previously. 20 Biopsies were homogenised (Precellys 24, Stretton Scientifi c Ltd, UK) in 10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 20 mM EDTA, 0.5% sodium dodecyl sulphate buffer and digested with proteinase K (Sigma-Aldrich) at a fi nal concentration of 0.2 mg/ml and incubated overnight at 56°C. The mtDNA was extracted using phenol-chloroform-isoamyl alcohol (25:24:1 by volume; Sigma) added in a 1:1 ratio with the lysed tissue, mixed thoroughly by shaking and centrifuged at >400 000×g for 10 min. The aqueous phase was gently removed from the top of the solution without disturbing the interphase. The aqueous solution was again mixed with phenol-chloroform-isoamyl alcohol in a 1:1 ratio and re-extracted. One-tenth volume of 3 M sodium acetate was added and the samples were precipitated with 2-2.5 volumes of ethanol. The DNA samples were resuspended in 50 μl 10 mM Tris-HCl. Ten micrograms of mtDNA were digested with 100 units of TaqαI restriction enzyme (New England BioLabs), 1×bovine serum albumin and a TaqαI-specifi c digestion buffer (10 mM Tris-HCl, 10 mM MgCl 2 , 100 mM NaCl, pH 8.4) for 10 h; 100 units of TaqαI being added to the reaction mixture every hour. PCR amplifi cation was performed in 25 μl reactions, containing 12.5 μl 2×SYBR Green Brilliant Mastermix (Stratagene), 0.1 μl uracil DNA glycosylase (New England Biosciences), 0.7 μl of 10 pM/μl forward and reverse primers (Integrated DNA Technologies) and 6.7 μl H 2 O. The samples were amplifi ed using a Roche Lightcycler 480 using the following protocol: 37°C for 10 min and 95°C for 10 min followed by 45 cycles of 95°C for 15 s, 60°C for 1 min. Samples were held at 72°C for 7 min and, following melt curve analysis, immediately stored at −80°C. The primer sequences used for identifying random mtDNA mutations at the 12S RNA site (bp 1215-1218) were 5′-CCTCAACAGTTAAATCAACAAAAC TGC-3′ (forward) and 5′-GCGCTTACTTTGTAGCCTTCA-3′ (reverse); the primer sequences used for mtDNA copy number quantifi cation were 5′-ACAGTTTATGTAGCTTACCTCC-3′ (forward) and 5′-TTGCTGCGTGCTTGATGCTTGT-3′ (reverse). All PCR products were sequenced to identify the mutation at the TaqαI recognition site (UW High Throughput sequencing facility, Seattle, USA).
Immunohistochemistry
Seven-micrometre OCT (Optimal Cutting Temperature media) sections were allowed to reach room temperature, fi xed in acetone for 10 min and air-dried. A routine three-stage immunoperoxidase labelling technique incorporating avidin-biotin immunoperoxidase complex (DAKO, Glostrup, Denmark) was used. Sections were incubated with primary mouse monoclonal anti-CD68 and anti-CD3 antibodies (DAKO, Glostrup, Denmark) at room temperature for 1 h. Sections were also incubated with an appropriate isotype matched mouse monoclonal antibody as a negative control. Colour was developed in solution containing diaminobenzadine tetrahydrochloride (Sigma-Aldrich, St Louis, Missouri, USA), 0.5% H 2 O 2 in phosphate buffered saline (pH 7.6). Slides were counterstained with haematoxylin and mounted. Slides were analysed using a well-established semiquantitative scoring method ranging from 0 to 4 (0=no staining, 1=<25%, 2=25-50%, 3=50-75%, 4=>75% staining). 1 4 21 22 Sections were scored separately for lining and sublining layers and results were expressed as the mean scores. 1 4 
MSD multi-array technology
The four-spot MSD human proinfl ammatory cytokine ultra sensitive kit, containing cytokines TNFα, IL-6, IFNγ and IL-1β (Meso Scale Discovery, Maryland, USA, Cat# K15009C-1) was used for the analysis of paired synovial fl uid samples. Quantifi cation was assessed using the Sector Imager 2400 (Meso Scale Delivery) instrument and software.
Primary RA and PsA synovial fi broblast culture RA and PsA synovial biopsies were digested with 1 mg/ml collagenase type 1 (Worthington Biochemical, Freehold, New Jersey, USA) in RPMI medium (Gibco-BRL, Paisley, UK) for 4 h at 37°C in humidifi ed air with 5% CO 2 . Dissociated cells were grown to confl uence in RPMI 1640, 10% FCS (Gibco-BRL), 10 ml of 1 mmol/l HEPES (Gibco-BRL), penicillin (100 units/ml; Biosciences), streptomycin (100 units/ml; Biosciences) and fungizone (0.25 ug/ ml; Bioscience) before passaging. Cells were used between passages 4 and 8. K4IM cells, an immortalised normal human synoviocyte cell line (kind gift, Dr Evelyn Murphy), were cultured as above and used between passages 35 and 38. RA synovial group.bmj.com on November 29, 2011 -Published by ard.bmj.com Downloaded from fi broblast cells (RASFCs), PsA synovial fi broblast cells (PsASFCs) and K4IM were seeded onto 96-well plates and into T25 fl asks and incubated with TNFα (10 ng/ml) for 24 h. mtDNA mutations, ROS, mitochondrial membrane potential (MMP) and mitochondrial mass (MM) were assessed as follows:
In vitro mitochondrial dysfunction
To determine the frequency of mtDNA point mutations, RASFC pellets were obtained following TNFα stimulation, were digested, purifi ed mtDNA was extracted and RMCA was performed as outlined above.
To measure the level of ROS, following TNFα stimulation, cells were washed twice with a buffer (130 mM NaCl, 5 mM KCl, 1 mM Na 2 HPO 4 , 1 mM CaCl 2 , 1 mM MgCl 2 and 25 mM Hepes, pH 7.4). Cells were loaded with 5 μM 2,7-dichlorofl uorescein diacetate (DCFH-DA) (Invitrogen) for 40 min at 37°C. DCFH-DA is a non-fl uorescent molecule which diffuses into the cells where it is deacetylated and rapidly oxidised to highly fl uorescent 2,7-dichlorofl uorescein in the presence of the generated ROS. DCF emits a fl uorescent signal of the product which is linearly related to the intracellular hydrogen peroxide concentration. To measure MMP, following TNFα stimulation, cells were washed and loaded with 5 μM rhodamine-123 (Sigma) for 40 min at 37°C. Rhodamine-123 is taken up selectively by mitochondria which is dependent on MMP. Following 40 min incubation, ROS and MMP probes were removed, cells were washed and analysed using the Spectra Max Gemini System. DCFH-DA and rhodamine-123 were excited at 485 nm, and fl uorescence emission at 538 nm was recorded. To measure MM, following TNFα stimulation, cells were incubated with Green-Fluorescent MitoTracker dye (Invitrogen). After group.bmj.com on November 29, 2011 -Published by ard.bmj.com Downloaded from incubation for 45 min, cells were visualised using a fl uorescence microscope. The probe has absorption and emission peaks at 490 and 516 nm, respectively, and the fl uorescence intensity is proportional to the MM. Mean fl uorescence values from four wells for each condition were obtained. Mitochondrial dysfunction assays were normalised to cell number.
Statistical analysis
SPSS15 system for Windows was used for statistical analysis. Non-parametric Wilcoxon signed rank, Spearman correlations with Bonferroni corrections and Mann-Whitney U test were used for analysis. p<0.05 was determined as statistically signifi cant.
RESULTS
Mutation of mtDNA in the synovium of active RA and PsA patients
A signifi cant increase in mtDNA mutations was demonstrated in RA and PsA synovial tissue (mean 4.8×10 −4 ) compared with normal synovium (7.3×10 −5 ) (p<0.013). When mtDNA mutations were analysed separately for RA and PsA synovium, signifi cantly higher mutation frequency was demonstrated for both RA and PsA compared with normal synovium (p=0.017 and p=0.041) (fi gure 1A). No signifi cant difference in mutation frequency was observed between RA and PsA (p=0.673) (fi gure 1A). The frequency of mtDNA mutations did not correlate with age in normal synovium (r=0.006, p=0.98) or in age-matched RA and PsA synovium (r=0.236, p=0.511) demonstrating that the increase in mtDNA mutation frequency was independent of age. The spectrum of mutations identifi ed demonstrated substitution of purines for pyrimidines in 49% of mutations and substitution of pyrimidines for purines in 51% of mutations (fi gure 1B).
Mutations in mtDNA correlate with macroscopic measures of infl ammation
Representative images of macroscopic synovitis and vascularity from a patient with low mtDNA mutations (fi gure 2A,D) versus high mtDNA mutations (fi gure 2B,E) are shown. Signifi cant correlation was demonstrated between mtDNA mutation frequency and macroscopic synovitis (r=0.52, p=0.016) and vascularity (r=0.55, p=0.01) suggesting that mtDNA mutation frequency is associated with the degree of infl ammation in the joint (fi gure 2C,F).
Mutations in mtDNA correlate with mediators of infl ammation
Synovial tissue mtDNA mutation frequency signifi cantly correlated with synovial fl uid expression of TNFα (r=0.74, p=0.024) and IFNγ (r=0.718, p=0.039) demonstrating a strong relationship between mitochondrial instability and proinfl ammatory pathways (table 1, see online supplementary fi gure 1). Associations Figure 3 Representative image of CD68+ sublining layer (SL) and CD3+ SL expression in infl amed synovial tissue from a patient with high frequency of mitochondrial DNA (mtDNA) mutation versus a patient with low frequency of mtDNA mutation. with CD68 sublining (r=0.5, p=0.052) and CD3 sublining layer expression (r=0.46, p=0.08) were observed, although following Bonferroni correction signifi cance was not reached (fi gure 3).
The effect of TNFi therapy on synovial mtDNA mutations
Synovial mtDNA mutations were decreased in patients following TNFi biologic therapy (n=15); however signifi cance was only achieved in patients with DAS28 score<3.2, where 6/7 patients showed a parallel decrease in clinical score and synovial mtDNA mutation frequency (p<0.05) (fi gure 4). A corresponding decrease in C reactive protein from 19 to 4 (p<0.05), swollen joint count from 3 to 0 (p<0.05), visual analogue scale from 60 to 20 mm (p<0.05) and DAS28 from 4.3 to 2.5 (p<0.05) was also demonstrated. Furthermore, signifi cant correlations between mtDNA mutation frequency and DAS28 (r=0.653, p<0.05) and sublining CD3 expression (r=0.485, p<0.05) was demonstrated. No signifi cant association was observed in patients whose DAS28 remained >3.2. No signifi cant difference was observed in baseline DAS28 in patients who achieved a DAS28<3.2 versus DAS28>3.2 post-TNFi therapy (p=0.325).
In vitro TNFα induces mitochondrial dysfunction in primary RASFC.
In RASFC, TNFα signifi cantly increased mtDNA mutation frequency from 6.62×10 −6 to 3.12×10 −5 (p<0.05) (fi gure 5A). In addition TNFα induced ROS production (p=0.007), MMP (p=0.045) and mitochondrial mass (p=0.023) compared with unstimulated control cells (fi gure 5B-D). In PsASFC, mtDNA mutations increased from 6.7x10 -6 to 9.9x10 -6 in response to TNFα (n=3, NS). In K4IM cells, basal mtDNA mutations were lower than RASFC/PsASFC, however increased from 5.02x10 -6 to 8.52x10 -6 following TNFα stimulation (p<0.05). In PsASFC and K4IM TNFα signifi cantly induced MMP (p<0.05), ROS production (p<0.05) and mitochondrial mass (p<0.05) (see online supplementary fi gures 2, 3).
DISCUSSION
In this study, we examine mitochondrial mutagenesis in patients with infl ammatory arthritis and assess its relationship to infl ammatory mechanisms in vivo and in vitro. We demonstrate that mitochondrial random mutations are signifi cantly increased in infl ammatory arthritis compared with normal synovial tissue. mtDNA mutations signifi cantly correlate with level of infl ammation at the macroscopic level. In particular, we demonstrate a signifi cant association between mtDNA mutation frequency and macroscopic/microscopic scores of infl ammation and proinfl ammatory cytokines: TNFα, IFNγ. Following TNFi biologic therapy, we demonstrate a signifi cant decrease in synovial mtDNA mutations. Finally in vitro, we show that TNFα stimulation drives mitochondrial dysfunction in primary RASFC and PsASFC along with mtDNA mutations.
In this study, we used a newly validated mitochondrial RMCA which relies on single-molecule amplifi cation to detect rare mutations among millions of wild-type bases and analyses mitochondrial mutagenesis at single base pair resolution and detects one mutation among 10 million wild-type bases. 20 Many mitochondrial point mutations associated with mitochondrial dysfunction have been characterised. 23 By assaying the random mutation frequency of a phenotypically neutral locus, 12S RNA, we estimate the likelihood at which any specifi c mitochondrial mutation and associated dysfunction, might occur. By using a TaqI site that does not span a protein coding region of the mitochondrial genome, we are able to extrapolate the extent of mutagenesis throughout the mitochondrial genome (ie, mutagenesis unaffected by phenotypic selection).
We demonstrated increased mtDNA mutation frequency in the infl amed synovium compared with normal controls, levels of which correlate with clinical measures of disease activity and with the local infl amed synovial tissue microenvironment. Our data is supported by previous studies showing increased levels of DNA damage and lipid peroxidation in patients with infl ammatory arthritis. 2 4 24 Signifi cantly higher levels of lipid peroxidation and depolarised mitochondria in RA peripheral blood mononuclear cells have been shown to correlate with disease activity. 24 Increased expression of 8-oxo-7,8-dihydro-2′-deoxyguanine and 4-hydroxy-2-nonenal have been demonstrated in RA synovial tissue and serum, and correlate with disease activity and angiogenic factors. 2 4 Increased clonal mtDNA mutation frequency in the MT-ND1 gene for mitochondrially encoded NADHdehydrogenase-1 has been detected in RASFC. 15 Furthermore potential mutation sites in the major histocompatibility complex epitope in RA patients, but not osteoarthritis, have been identifi ed suggesting mtDNA may become antigenic and drive immune mediated responses. In mouse fi broblasts, TNFR1 mutant cells show evidence of altered mitochondrial function, resulting in increased oxidative capacity, mitochondrial ROS generation and proinfl ammatory cytokines. 15 In addition, in vivo synovial tissue oxygen levels correlate with oxidative damage and mitochondrial dysfunction. 25 Mitochondrially derived ROS can induce TNFα cytotoxicity and may mediate the activation of transcriptional factor NF-κB which in turn can stimulate mitochondrial NADPH oxidase. 26 27 TNFR1 mutant cells exhibit altered mitochondrial function, increased production of IL-6, TNFα, IL-8 and phosphorylation of mitogen-activated protein kinase pathways. 15 Altered mitochondrial membrane permeability and Bcl-X overexpression group.bmj.com on November 29, 2011 -Published by ard.bmj.com Downloaded from leads to resistance to TNF cytoxicity. 28 Combination of IL-1β and IFNγ can induce mitochondrial Bax translocation, cytochrome c release and caspase-3 cleavage. 29 In addition, ROS can mediate IL-1-induced experimental arthritis, 30 and cyclooxygenase-2 expression in RASFC. 31 CD3+ T cells and CD68+ macrophages are potent producers of cytokines critical to synovial infl ammation. 32 33 In this study, reduction of synovial mtDNA mutation frequency and its association with measures of clinical disease activity and microscopic CD3+ cells following TNFi therapy, strengthens the hypothesis of a pathological link between mitochondrial dysfunction and pro-infl ammatory pathways.
We have shown using RASFC that TNFα signifi cantly increases mtDNA mutation frequency, coupled with increased ROS production, MMP and MM, thus recapitulating the in vivo responses to TNFi therapy. This is consistent with mice models showing interactions between oxidatively damaged mtDNA, increased NF-κB activity and TNFα production. 30 TNFα increases mitochondrial ROS production and induces lipid-derived aldehyde formation. 26 34-38 High mutations were demonstrated at baseline in TNFi non-responders suggesting TNF independent pathways may be involved in mtDNA mutations. We and others previously showed strong associations between mitochondrial dysfunction and synovial tissue oxidative stress, angiogenic growth factors and cytokines. 4 29-31 Furthermore, hypoxia can increase mtDNA mutations in primary RA synoviocytes. 25 Direct functional consequences of mitochondrial random mutations in infl ammation are unclear; however, they may have an important role in the regulation of the innate immune response. 39 Zhou et al, have demonstrated that the NLRP3 infl ammasome can sense mitochondrial dysfunction, altering the infl ammatory response. 40 Furthermore, mitochondrial dysfunction regulates IL-1 and IL-18 secretion from macrophages in response to lipopolysaccharide. 41 Additionally in an experimental arthritis model, manipulation of mitochondrial pathways reduces severity of cartilage lesions and synovial infl ammation. 42 
